<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611242</url>
  </required_header>
  <id_info>
    <org_study_id>0525052522</org_study_id>
    <nct_id>NCT05611242</nct_id>
  </id_info>
  <brief_title>Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial</brief_title>
  <acronym>PICASSO</acronym>
  <official_title>Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Health Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Health Ohio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to establish the efficacy of intra-arterial (IA) mechanical&#xD;
      thrombectomy with proximal carotid artery angioplasty versus acute stenting during&#xD;
      thrombectomy in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion&#xD;
      (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or&#xD;
      severe stenosis) within 24 hours of symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Independent Investigator-initiated, designed and conducted non-industry study. A prospective,&#xD;
      phase III, randomized, open-label, blinded-endpoint controlled trial (PROBE Design).&#xD;
&#xD;
      Patients presenting with symptoms of AIS in the anterior circulation with proximal carotid&#xD;
      occlusive disease will be assigned to either best medical management (BMM)+/-intra-arterial&#xD;
      treatment (IAT) with mechanical thrombectomy (for IVO) added to proximal extra-cranial&#xD;
      carotid occlusion none stenting thrombectomy treatment (CAT) none stenting: angioplasty,&#xD;
      aspiration or atherectomy) (BMM+/-IAT+CAT without stenting) approach VERSUS BMM+/-IAT with&#xD;
      added carotid thrombectomy using stenting (BMM+/-IAT+CAT with Stenting) approach.&#xD;
&#xD;
      Randomization will be 1:1, with stratification by: 1) age, 2) National Institute of Health&#xD;
      Stroke Scale (NIHSS), 3) degree of proximal extra-cranial carotid stenosis (complete&#xD;
      occlusion versus stenosis), 4) IV lytic administration, 5) time from onset to randomization&#xD;
      CTA imaging confirming ICA occlusion/tandem lesion, 6) and ASPECT score.&#xD;
&#xD;
      Within the stenting arm, there will be 3 different subgroups based on the antiplatelet&#xD;
      treatment protocol per the site standard of care (Single antiplatelet, dual oral antiplatelet&#xD;
      or IV antiplatelet medication (e.g.Cangrelor or others). Each arm will be assessed at the&#xD;
      first interim analysis to consider dropping an arm; if predetermined safety boundaries are&#xD;
      exceeded.&#xD;
&#xD;
      Mechanical thrombectomy and proximal angioplasty or stenting will be performed with an&#xD;
      FDA-cleared devices in accordance with the instructions for use (IFU). The order of each&#xD;
      procedure (revascularization of the proximal extra-cranial carotid lesion first or after the&#xD;
      intracranial lesion) will be left at discretion of the treating proceduralist.&#xD;
&#xD;
      Each treated patient will be followed and assessed for the primary outcome at 3 months and&#xD;
      one year after randomization by an independent adjudicator not involved in the procedure.&#xD;
      Optional utilization of remote assessment of NIHSS, mRS scale may be provided to selected&#xD;
      site (NeuroMerit Clinical Core Lab).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Independent Investigator-initiated, designed and conducted non-industry study. A prospective, phase III, randomized, open-label, blinded-endpoint controlled trial (PROBE Design).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Utility-weighted 90-day Modified Rankin Score</measure>
    <time_frame>Time Frame: 90 days post randomization</time_frame>
    <description>Scale used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scale ranges from 0-6 where 0 represents no symptoms and 6 represents death.&#xD;
0 = No symptoms at all.&#xD;
No significant disability despite symptoms; able to carry out all usual duties and activities.&#xD;
Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.&#xD;
Moderate disability requiring some help, but able to walk without assistance.&#xD;
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.&#xD;
Severe disability; bedridden, incontinent, and requiring constant nursing care and attention.&#xD;
Death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>BMM+/-IAT+CAT with Stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Best Medical Management (BMM) +/- Intra-arterial Therapy (IAT) with added carotid thrombectomy (CAT) using stenting approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMM+/-IAT+CAT without stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Best Medical Management (BMM)+/-intra-arterial treatment (IAT) with mechanical thrombectomy (for IVO) added to proximal extra-cranial carotid occlusion none stenting thrombectomy treatment (CAT) none stenting: angioplasty, aspiration or atherectomy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-arterial Therapy</intervention_name>
    <description>Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.</description>
    <arm_group_label>BMM+/-IAT+CAT with Stenting</arm_group_label>
    <arm_group_label>BMM+/-IAT+CAT without stenting</arm_group_label>
    <other_name>Thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Drug</intervention_name>
    <description>Within the stenting arm, there will be 3 different subgroups based on the antiplatelet treatment protocol per the site standard of care (Single antiplatelet, dual oral antiplatelet or IV antiplatelet medication (e.g.Cangrelor or others). Each arm will be assessed at the first interim analysis to consider dropping an arm; if predetermined safety boundaries are exceeded.</description>
    <arm_group_label>BMM+/-IAT+CAT with Stenting</arm_group_label>
    <other_name>Cangrelor</other_name>
    <other_name>Plavix</other_name>
    <other_name>Tricagrelor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMBOGUARD Balloon Guide Catheter</intervention_name>
    <description>Mechanical thrombectomy and proximal angioplasty or stenting will be performed with an FDA-cleared devices in accordance with the instructions for use (IFU). The order of each procedure (revascularization of the proximal extra-cranial carotid lesion first or after the intracranial lesion) will be left at discretion of the treating proceduralist.</description>
    <arm_group_label>BMM+/-IAT+CAT with Stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 85 years of age&#xD;
&#xD;
          2. Presenting with symptoms consistent with AIS&#xD;
&#xD;
          3. Imaging evidence of an anterior circulation occlusion of the Internal Carotid Artery&#xD;
             (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1), or proximal M2&#xD;
             segment AND extra-cranial proximal carotid occlusion / severe stenosis requiring&#xD;
             treatment on non-invasive imaging ≥70%&#xD;
&#xD;
          4. NIHSS ≥ 4&#xD;
&#xD;
          5. Ability to randomize within 24 hours of stroke onset&#xD;
&#xD;
          6. Pre-stroke mRS score 0-2&#xD;
&#xD;
          7. Ability to obtain signed informed consent&#xD;
&#xD;
          8. ASPECTS Score ≥ 6 by CT scan or MRI (DWI) ≤6hours from stroke onset, and ASPECT &gt;6&#xD;
             (7-10) OR Core≤50cc on MRP, CTP or MRI &gt;6h-24 hours from stroke onset, given the need&#xD;
             for antiplatelet therapy&#xD;
&#xD;
          9. Imaging obtained within 24 hours (after the first symptoms or last seen well.&#xD;
&#xD;
         10. Arterial Access Obtained &lt; 25 hours from stroke symptoms onset.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, or those of child-bearing potential with positive urine or&#xD;
             serum beta Human Chorionic Gonadotropin (HCG) test&#xD;
&#xD;
          2. Known severe allergy (more than a rash) to contrast media uncontrolled by medications&#xD;
&#xD;
          3. Refractory hypertension (defined as persistent systolic blood pressure &gt;185 mmHg or&#xD;
             diastolic blood pressure &gt;110 mmHg) despite medication&#xD;
&#xD;
          4. CT evidence of the following conditions:&#xD;
&#xD;
               -  Midline shift or herniation&#xD;
&#xD;
               -  Evidence of intracranial hemorrhage&#xD;
&#xD;
               -  Mass effect with effacement of the ventricles&#xD;
&#xD;
          5. Acute bilateral strokes&#xD;
&#xD;
          6. Contraindication to antiplatelet (Aspirin, Plavix, Ticagrelor, Cangrelor), or&#xD;
             thrombolytic therapy, or contrast agents.&#xD;
&#xD;
          7. Intracranial tumors other than small meningioma that doesn't not require surgery for&#xD;
             one year post randomization&#xD;
&#xD;
          8. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant&#xD;
             therapy with an International Normalized Ratio (INR) of &gt;3.0 or Partial Thromboplastin&#xD;
             Time (PTT) &gt; 3 times of normal&#xD;
&#xD;
          9. Baseline platelet count &lt;30,000 per microliter (µl)&#xD;
&#xD;
         10. Life expectancy less than one year prior to stroke onset&#xD;
&#xD;
         11. Participation in another randomized clinical trial that could confound the evaluation&#xD;
             of the study outcomes&#xD;
&#xD;
         12. Any other condition (in the opinion of the site investigator) that precludes an&#xD;
             endovascular procedure or poses a significant hazard to the patient if an endovascular&#xD;
             procedure was performed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama O Zaidat, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Health St. Vincent Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah D Slight, BS</last_name>
    <phone>419-251-2338</phone>
    <email>hplummer1@mercy.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanner J Gray-DuVall, BS</last_name>
    <email>tgray-duvall@mercy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Health St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osama O Zaidat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 2, 2022</last_update_submitted>
  <last_update_submitted_qc>November 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Health Ohio</investigator_affiliation>
    <investigator_full_name>Dr. Osama O. Zaidat</investigator_full_name>
    <investigator_title>Neuroscience and Stroke Medical Director</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cangrelor</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All shared data will be aggregate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

